Dabigatran Etexilate Sandoz: Uses, Dosage & Side Effects
A direct oral anticoagulant (DOAC) that prevents blood clots by directly inhibiting thrombin, used for stroke prevention in atrial fibrillation and treatment of venous thromboembolism
Dabigatran etexilate Sandoz is a direct oral anticoagulant (DOAC) containing dabigatran etexilate, a prodrug that is rapidly converted to its active form dabigatran after oral administration. Dabigatran works by directly and reversibly inhibiting thrombin (factor IIa), a key enzyme in the blood clotting cascade, thereby preventing the formation of blood clots. It is used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation, to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), to prevent recurrence of DVT and PE, and to prevent venous thromboembolism after elective hip or knee replacement surgery. Dabigatran etexilate Sandoz is a generic formulation that is bioequivalent to the originator product Pradaxa and requires a prescription.
Quick Facts: Dabigatran Etexilate Sandoz
Key Takeaways
- Dabigatran etexilate Sandoz is a direct oral anticoagulant (DOAC) that works by directly inhibiting thrombin to prevent blood clot formation, offering a predictable anticoagulant effect without the need for routine blood monitoring (INR testing).
- It is approved for preventing stroke in non-valvular atrial fibrillation, treating and preventing DVT/PE, and preventing venous thromboembolism after hip or knee replacement surgery – but must never be used in patients with mechanical heart valves.
- Kidney function is critical: dabigatran is primarily excreted by the kidneys (80%), so dose adjustments are required in moderate renal impairment (CrCl 30–50 mL/min) and the drug is contraindicated in severe renal impairment (CrCl <30 mL/min).
- A specific reversal agent, idarucizumab (Praxbind), is available for emergency situations requiring rapid reversal of the anticoagulant effect, such as life-threatening bleeding or urgent surgery.
- Capsules must be swallowed whole (never opened or crushed), stored in original packaging to protect from moisture, and used within 4 months once a bottle is opened.
What Is Dabigatran Etexilate Sandoz and What Is It Used For?
Dabigatran etexilate Sandoz contains the active substance dabigatran etexilate mesilate, which belongs to a class of medicines known as direct oral anticoagulants (DOACs), sometimes also called novel oral anticoagulants (NOACs). Unlike older anticoagulants such as warfarin, which act indirectly by interfering with vitamin K-dependent clotting factor synthesis in the liver, dabigatran works by directly and specifically inhibiting thrombin (also known as coagulation factor IIa). Thrombin plays a central role in the blood coagulation cascade: it converts soluble fibrinogen into insoluble fibrin strands, which form the structural framework of a blood clot. By blocking thrombin, dabigatran effectively prevents the final common pathway of clot formation.
Dabigatran etexilate itself is a prodrug, meaning it is pharmacologically inactive until it is absorbed from the gastrointestinal tract and converted to its active form, dabigatran, by esterase enzymes in the plasma and liver. This conversion occurs rapidly, with peak plasma concentrations of the active compound reached within 0.5 to 2 hours after oral administration. One of the key advantages of dabigatran over vitamin K antagonists is its predictable, dose-proportional pharmacokinetic profile, which eliminates the need for routine anticoagulation monitoring through blood tests such as the international normalized ratio (INR). This represents a significant improvement in convenience and quality of life for patients requiring long-term anticoagulation.
Dabigatran etexilate Sandoz is a generic formulation that has been demonstrated to be bioequivalent to the originator product Pradaxa, meaning it delivers the same amount of active drug to the body at the same rate. Generic medicines undergo rigorous regulatory review by authorities such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) to ensure they meet the same standards of quality, safety, and efficacy as the originator product. Patients can be confident that switching between the originator and generic formulations, when approved by their healthcare provider, should not result in any clinically meaningful difference in therapeutic effect.
The approved indications for dabigatran etexilate Sandoz are based on the robust clinical trial evidence established for dabigatran, including several landmark randomized controlled trials:
- Prevention of stroke and systemic embolism in non-valvular atrial fibrillation (NVAF): Atrial fibrillation is the most common sustained cardiac arrhythmia, affecting millions of people worldwide. It causes the upper chambers of the heart (atria) to beat irregularly and often rapidly, which allows blood to pool and form clots. These clots can travel to the brain and cause a stroke. The RE-LY trial (Randomized Evaluation of Long-term Anticoagulant Therapy), a landmark study of over 18,000 patients, demonstrated that dabigatran 150 mg twice daily was superior to warfarin in preventing stroke and systemic embolism, while dabigatran 110 mg twice daily was non-inferior to warfarin with a significantly lower rate of major bleeding.
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE): DVT occurs when a blood clot forms in a deep vein, usually in the legs, while PE occurs when a clot breaks free and travels to the lungs. The RE-COVER and RE-COVER II trials demonstrated that dabigatran 150 mg twice daily (after initial parenteral anticoagulation for 5–10 days) was non-inferior to warfarin for the treatment of acute DVT and PE, with a favorable bleeding profile.
- Prevention of recurrent DVT and PE: The RE-MEDY and RE-SONATE trials showed that extended treatment with dabigatran significantly reduced the risk of recurrent venous thromboembolism. In RE-SONATE, dabigatran reduced the relative risk of recurrence by 92% compared with placebo over a 6-month treatment period.
- Prevention of venous thromboembolism (VTE) after elective hip or knee replacement surgery: The RE-MODEL, RE-NOVATE, RE-NOVATE II, and RE-MOBILIZE trials demonstrated that dabigatran was effective in preventing VTE following major orthopedic surgery, with a safety profile comparable to enoxaparin, the standard of care.
Dabigatran is unique among the DOACs in that it directly inhibits thrombin (factor IIa), rather than factor Xa (which is the target of rivaroxaban, apixaban, and edoxaban). By binding directly to the active site of both free and clot-bound thrombin, dabigatran prevents thrombin from converting fibrinogen to fibrin and also inhibits thrombin-induced platelet aggregation. This dual mechanism provides comprehensive anticoagulant activity at the endpoint of the coagulation cascade.
What Should You Know Before Taking Dabigatran Etexilate Sandoz?
Contraindications
There are several important situations in which dabigatran etexilate must not be used. Understanding these absolute contraindications is essential for safe prescribing and patient safety. Your doctor will assess these factors before initiating treatment.
- Hypersensitivity: Do not take dabigatran if you are allergic to dabigatran etexilate mesilate or any of the excipients in the capsule formulation. Signs of a severe allergic reaction include rash, swelling of the face or throat, difficulty breathing, or a drop in blood pressure.
- Severe renal impairment: Dabigatran is predominantly eliminated by the kidneys (approximately 80% of the administered dose). In patients with severe renal impairment (creatinine clearance <30 mL/min), drug levels accumulate to dangerously high concentrations, significantly increasing bleeding risk. Dabigatran is contraindicated in these patients.
- Active clinically significant bleeding: Dabigatran must not be used in patients with ongoing serious bleeding, such as gastrointestinal hemorrhage, intracranial bleeding, or any other clinically significant hemorrhage.
- Organ lesions at risk of bleeding: Conditions such as current or recent gastrointestinal ulceration, the presence of malignant neoplasms at high bleeding risk, recent brain or spinal injury, recent brain, spinal, or ophthalmic surgery, recent intracranial hemorrhage, known or suspected esophageal varices, arteriovenous malformations, vascular aneurysms, or major intraspinal or intracerebral vascular abnormalities.
- Concomitant treatment with other anticoagulants: Dabigatran must not be used simultaneously with unfractionated heparin (except at doses used to maintain central venous or arterial catheters), low molecular weight heparins, heparin derivatives, oral anticoagulants (warfarin, rivaroxaban, apixaban, etc.), except when switching between these agents under medical supervision.
- Hepatic impairment or liver disease expected to impact survival: Patients with severe liver disease should not take dabigatran, as liver dysfunction can impair the conversion of the prodrug and affect coagulation factor synthesis.
- Concomitant treatment with systemic ketoconazole, cyclosporine, itraconazole, dronedarone, or glecaprevir/pibrentasvir: These drugs are potent inhibitors of P-glycoprotein (P-gp), a transport protein involved in the absorption and renal clearance of dabigatran. Co-administration results in significantly increased dabigatran levels and unacceptable bleeding risk.
- Prosthetic heart valves requiring anticoagulant treatment: The RE-ALIGN trial was terminated early because dabigatran was associated with increased rates of thromboembolic events and major bleeding in patients with mechanical heart valves compared with warfarin. Dabigatran must not be used in this population.
Warnings and Precautions
All anticoagulants, including dabigatran, increase the risk of bleeding. Serious and potentially fatal bleeding events have been reported. Seek immediate medical attention if you experience signs of bleeding such as unusual bruising, prolonged bleeding from cuts, blood in your urine or stool, black tarry stools, coughing up blood, vomiting blood, severe headache, dizziness, or weakness. A specific reversal agent, idarucizumab (Praxbind), is available for emergency reversal of dabigatran’s anticoagulant effect.
Before and during treatment with dabigatran etexilate, your doctor should be aware of the following conditions and risk factors that require special attention:
- Renal function monitoring: Because dabigatran is primarily cleared by the kidneys, renal function (creatinine clearance) must be assessed before treatment is started and should be monitored at least annually during treatment, or more frequently in situations where renal function may decline (dehydration, hypovolemia, concomitant nephrotoxic drugs, elderly patients over 75 years). If creatinine clearance falls below 30 mL/min, dabigatran must be discontinued.
- Age over 75 years: Elderly patients have an increased risk of bleeding, partly due to age-related decline in kidney function. The lower dose (110 mg twice daily) may be recommended in this population depending on the indication, and close monitoring is essential.
- Low body weight (<50 kg): Patients with very low body weight may have higher drug exposure and an increased bleeding risk. Close clinical monitoring is recommended.
- Gastrointestinal bleeding risk: Dabigatran may increase the risk of gastrointestinal bleeding, particularly in elderly patients. Concomitant use of antiplatelet agents (aspirin, clopidogrel), non-steroidal anti-inflammatory drugs (NSAIDs), or selective serotonin reuptake inhibitors (SSRIs) further increases this risk.
- Surgical procedures: Dabigatran should be temporarily discontinued before invasive or surgical procedures. The duration of interruption depends on renal function and the bleeding risk of the procedure. For standard-risk procedures, dabigatran should be stopped at least 24 hours before surgery; for high-risk procedures, at least 48 hours. Your doctor or surgeon will provide specific guidance.
- Spinal/epidural anesthesia or puncture: There is a risk of spinal or epidural hematoma with neuraxial anesthesia in patients taking anticoagulants, which can result in long-term or permanent paralysis. The timing of catheter placement and removal must be carefully coordinated with dabigatran dosing.
- Interstitial lung disease: Cases of interstitial lung disease have been reported during dabigatran treatment. If respiratory symptoms develop (dyspnea, cough), further investigation should be performed.
Pregnancy and Breastfeeding
There are limited data on the use of dabigatran etexilate in pregnant women. Animal studies have shown reproductive toxicity, including reduced fetal body weight and increased fetal variations at high doses. As a precautionary measure, dabigatran should be avoided during pregnancy unless the potential clinical benefit clearly outweighs the potential risk to the fetus. Women of childbearing potential should use effective contraception during treatment.
It is not known whether dabigatran or its metabolites are excreted in human breast milk. In animal studies, dabigatran was detected in the milk of lactating rats. A risk to the breastfed infant cannot be excluded, and therefore breastfeeding should be discontinued during treatment with dabigatran etexilate. Your doctor will help you weigh the benefits of breastfeeding against the need for anticoagulation treatment.
There are no adequate human data on the effect of dabigatran on fertility. In preclinical animal studies, no adverse effects on fertility were observed at clinically relevant doses. However, a decrease in implantations and an increase in pre-implantation losses were seen at maternally toxic doses. If you are planning to become pregnant, discuss with your doctor whether your anticoagulation treatment needs to be adjusted.
Never stop taking dabigatran without first talking to your doctor. Stopping anticoagulation abruptly in patients with atrial fibrillation increases the risk of stroke. If dabigatran needs to be discontinued for reasons other than pathological bleeding, your doctor may consider transitioning you to another anticoagulant to maintain protection against blood clots.
How Does Dabigatran Etexilate Sandoz Interact with Other Drugs?
Unlike many other drugs, dabigatran etexilate is not significantly metabolized by the cytochrome P450 (CYP) enzyme system, which means it has fewer drug interactions related to hepatic metabolism. However, it is a substrate of the efflux transporter P-glycoprotein (P-gp), and interactions with P-gp inhibitors and inducers are clinically important. P-gp is expressed in the intestinal epithelium and the renal tubular epithelium, where it plays a role in both the absorption and renal clearance of dabigatran. Medications that inhibit P-gp can increase dabigatran absorption and reduce its renal clearance, leading to higher plasma levels and an increased risk of bleeding. Conversely, P-gp inducers can reduce dabigatran levels, potentially compromising its therapeutic effectiveness.
It is essential to inform your doctor about all medications you are currently taking or have recently taken, including prescription drugs, over-the-counter medications, herbal supplements, and dietary supplements. The following tables summarize the most clinically important interactions.
Major Interactions
| Interacting Drug | Mechanism | Clinical Significance |
|---|---|---|
| Ketoconazole | Potent P-gp inhibitor; increases dabigatran AUC by 138–153% | Contraindicated – never combine |
| Dronedarone | Potent P-gp inhibitor; increases dabigatran exposure substantially | Contraindicated – never combine |
| Itraconazole | Potent P-gp inhibitor; significantly increases dabigatran levels | Contraindicated – never combine |
| Cyclosporine | Potent P-gp inhibitor; markedly increases dabigatran exposure | Contraindicated – never combine |
| Glecaprevir/Pibrentasvir | P-gp inhibitors; increase dabigatran exposure | Contraindicated – never combine |
| Rifampicin | Potent P-gp inducer; reduces dabigatran AUC by approximately 66% | Avoid – significantly reduces anticoagulant effect |
| St. John’s Wort | P-gp inducer; reduces dabigatran plasma levels | Avoid – reduces anticoagulant effect |
| Carbamazepine / Phenytoin | P-gp inducers; reduce dabigatran exposure | Avoid – expected to reduce anticoagulant effect |
Moderate Interactions Requiring Dose Adjustment or Monitoring
| Interacting Drug | Mechanism | Clinical Action |
|---|---|---|
| Verapamil | P-gp inhibitor; increases dabigatran AUC by 12–180% depending on timing and formulation | Take dabigatran at least 2 hours before verapamil; dose reduction may be needed (110 mg twice daily for NVAF) |
| Amiodarone | P-gp inhibitor; increases dabigatran AUC by approximately 50–60% | Monitor closely; dose reduction to 150 mg twice daily may be considered in some patients at higher bleeding risk |
| Quinidine | P-gp inhibitor; increases dabigatran levels | Monitor closely for signs of bleeding |
| Clarithromycin | P-gp inhibitor; may increase dabigatran exposure | Monitor for signs of bleeding; clinical monitoring recommended |
| Ticagrelor | P-gp inhibitor; increases dabigatran Cmax by 65% and AUC by 27% | Caution; increased bleeding risk when combined |
| NSAIDs / Aspirin / Clopidogrel | Additive bleeding risk through antiplatelet and gastrointestinal mucosal effects | Use with caution; increased risk of gastrointestinal and other bleeding |
| SSRIs / SNRIs | Impair platelet function; additive bleeding risk | Monitor for signs of bleeding |
Unlike warfarin and some other DOACs, dabigatran etexilate is not significantly metabolized by cytochrome P450 enzymes (CYP3A4, CYP2C9, etc.). This means it has a much lower potential for interactions with the large number of drugs metabolized by these enzymes, including many antibiotics, antifungals, and anti-epileptic drugs. However, P-gp interactions remain clinically important and must be carefully managed.
What Is the Correct Dosage of Dabigatran Etexilate Sandoz?
The dosage of dabigatran etexilate Sandoz varies according to the indication being treated, the patient’s age, kidney function, and individual risk factors. It is essential to follow your doctor’s prescribed dosage exactly and not to adjust the dose on your own. The capsules should be taken with a full glass of water, with or without food, and must be swallowed whole – they must never be opened, crushed, broken, or chewed, as this dramatically increases bioavailability and the risk of serious bleeding.
Adults – Stroke Prevention in Atrial Fibrillation
Standard Dose
150 mg twice daily (one 150 mg capsule in the morning and one in the evening, approximately 12 hours apart). This is the recommended dose for most adult patients under 80 years of age with a creatinine clearance ≥50 mL/min.
Reduced Dose
110 mg twice daily is recommended for patients aged 80 years and older. It should also be considered for patients aged 75–80 years with additional bleeding risk factors, patients with moderate renal impairment (CrCl 30–50 mL/min), patients taking verapamil concurrently, or those with gastritis, esophagitis, or gastroesophageal reflux.
Adults – Treatment of DVT and PE
Acute Treatment Phase
Dabigatran must be initiated only after at least 5 days of parenteral anticoagulation (e.g., heparin or low molecular weight heparin). The dose is then 150 mg twice daily. For patients aged 80 years and older or those on concomitant verapamil, the dose should be reduced to 110 mg twice daily.
Extended Prevention of Recurrent DVT/PE
150 mg twice daily (or 110 mg twice daily for patients ≥80 years). The duration of treatment is individualized based on the patient’s risk of recurrence versus bleeding risk. There is no fixed maximum duration.
Adults – VTE Prevention After Hip or Knee Replacement
Starting Dose
110 mg taken 1–4 hours after completion of surgery, followed by 220 mg once daily (two 110 mg capsules taken together) on subsequent days. For patients over 75 years, those with moderate renal impairment (CrCl 30–50 mL/min), or those receiving concomitant verapamil, the starting dose is 75 mg followed by 150 mg once daily.
Duration of Treatment
After knee replacement: 10 days. After hip replacement: 28–35 days. Treatment should begin on the day of surgery, 1–4 hours after the procedure, provided hemostasis has been secured.
Children and Adolescents
Dabigatran etexilate Sandoz (75 mg hard capsules) is not indicated for use in children or adolescents under 18 years of age for the approved adult indications. Pediatric formulations of dabigatran (oral pellets) may be available in some markets for specific pediatric indications (treatment of venous thromboembolism in children), but these use different dosing regimens based on age and weight. The hard capsule formulation discussed here is intended for adult use only.
Elderly Patients
Elderly patients are at increased risk of both thromboembolic events and bleeding complications. In patients aged 75–80 years, the choice between 150 mg and 110 mg twice daily should be based on an individual assessment of thromboembolic risk versus bleeding risk. For patients aged 80 years and older with NVAF, the recommended dose is 110 mg twice daily. Kidney function should be monitored at least every 6 months in elderly patients, as age-related renal decline can lead to drug accumulation and increased bleeding risk.
Missed Dose
If you forget to take a dose of dabigatran, take it as soon as you remember on the same day. If it is less than 6 hours until your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to compensate for the missed one. Missing doses can increase your risk of stroke or blood clots, so try to take dabigatran at regular times each day to help you remember.
Overdose
There is no specific antidote for dabigatran in the conventional sense; however, idarucizumab (Praxbind) is a specific reversal agent that is approved for use in emergency situations. Idarucizumab is a humanized monoclonal antibody fragment (Fab) that binds to dabigatran with approximately 350 times greater affinity than thrombin, rapidly and completely neutralizing dabigatran’s anticoagulant effect within minutes of intravenous administration.
In case of suspected overdose without life-threatening bleeding, management is primarily supportive: discontinue the drug, maintain adequate diuresis (dabigatran is dialyzable, and hemodialysis can remove approximately 60% of the drug within 2–3 hours), and consider oral activated charcoal if the overdose occurred within 1–2 hours. For life-threatening bleeding or emergency surgery, idarucizumab (5 g intravenous) should be administered. If idarucizumab is not available, consider prothrombin complex concentrate (PCC) or activated PCC, though these are less specific.
If you suspect an overdose, contact your local poison control center or emergency department immediately. Symptoms of overdose include unusual or excessive bleeding from cuts, gums, nose, or other sites, blood in urine or stool, and prolonged bleeding that does not stop. Do not wait for symptoms to worsen before seeking medical attention.
What Are the Side Effects of Dabigatran Etexilate Sandoz?
Like all medicines, dabigatran etexilate can cause side effects, although not everybody gets them. The most important side effect is bleeding, which is an expected consequence of the drug’s anticoagulant mechanism of action. The risk of bleeding depends on several factors including dose, patient age, kidney function, body weight, and concomitant medications. In the landmark RE-LY trial, dabigatran 150 mg twice daily had a similar rate of major bleeding to warfarin, while dabigatran 110 mg twice daily had a significantly lower rate of major bleeding. However, both doses were associated with a higher rate of gastrointestinal bleeding compared with warfarin.
The following side effects have been reported during clinical trials and post-marketing surveillance. They are organized by frequency according to standard medical convention:
Common
May affect up to 1 in 10 people
- Gastrointestinal hemorrhage (stomach or bowel bleeding)
- Dyspepsia (indigestion, stomach discomfort)
- Abdominal pain or discomfort
- Nausea
- Diarrhea
- Epistaxis (nosebleeds)
- Urogenital bleeding (blood in urine or genital tract bleeding)
- Decreased hemoglobin (lower red blood cell levels)
- Skin bleeding (bruising, bleeding from wounds)
Uncommon
May affect up to 1 in 100 people
- Intracranial hemorrhage (bleeding inside the skull)
- Hematoma (collection of blood under the skin or in tissues)
- Hemoptysis (coughing up blood)
- Rectal bleeding
- Hemorrhoidal bleeding
- Gastrointestinal ulceration
- Gastroesophagitis (inflammation of stomach and esophagus)
- Gastroesophageal reflux disease
- Vomiting
- Dysphagia (difficulty swallowing)
- Abnormal liver function tests / elevated transaminases
- Hypersensitivity reactions (rash, pruritus)
- Wound bleeding or post-procedural hemorrhage
- Traumatic bleeding
- Thrombocytopenia (low platelet count)
- Anemia (low red blood cell count)
Rare
May affect up to 1 in 1,000 people
- Anaphylactic reaction (severe allergic reaction)
- Angioedema (swelling of face, lips, tongue, or throat)
- Urticaria (hives)
- Bronchospasm
- Hepatic function abnormal / hepatocellular damage
- Injection site bleeding (at venipuncture or catheter sites)
Not Known
Frequency cannot be estimated from available data
- Esophageal ulcer
- Alopecia (hair loss)
- Skin rash
In the RE-LY trial, the rate of major bleeding with dabigatran 150 mg twice daily was 3.11% per year compared with 3.36% per year with warfarin (not significantly different). With dabigatran 110 mg twice daily, the rate was 2.71% per year (significantly lower than warfarin). The rate of intracranial hemorrhage was significantly lower with both doses of dabigatran compared with warfarin (0.30% and 0.23% per year for dabigatran 150 mg and 110 mg, respectively, versus 0.74% per year for warfarin). However, the rate of major gastrointestinal bleeding was higher with dabigatran 150 mg (1.51% per year) compared with warfarin (1.02% per year).
Dabigatran-related dyspepsia (which includes symptoms such as epigastric pain, abdominal discomfort, bloating, and nausea) occurred in approximately 11% of patients in clinical trials. This is thought to be related to the tartaric acid core of the capsule formulation, which creates an acidic microenvironment to enhance absorption. Taking the capsules with food or with a proton pump inhibitor (PPI) may help alleviate these symptoms, although PPIs slightly reduce dabigatran bioavailability (by approximately 20–30%), which is not considered clinically significant.
Contact your doctor or go to the nearest emergency department immediately if you experience: severe or uncontrollable bleeding from any site; blood in your vomit, urine, or stool (or black tarry stool); sudden severe headache, confusion, weakness, or vision changes (possible intracranial bleeding); swelling of the face, lips, tongue, or throat with difficulty breathing (possible allergic reaction); or severe abdominal pain that does not go away.
How Should You Store Dabigatran Etexilate Sandoz?
Proper storage of dabigatran etexilate Sandoz capsules is critically important because the active ingredient is sensitive to moisture. Exposure to moisture can degrade the capsules and significantly affect their potency and efficacy. Unlike many other oral medications, dabigatran capsules must not be removed from their original packaging until the moment they are taken.
- Temperature: Store below 30°C. Do not refrigerate or freeze.
- Moisture protection: Keep the capsules in their original blister packaging or in the original bottle with the cap tightly closed. The blister packaging and bottle contain desiccants to protect against moisture – do not remove these.
- Do not use pill organizers: Never transfer dabigatran capsules to weekly pill boxes, dosette boxes, or any other container. These do not provide adequate moisture protection and can lead to degraded capsules.
- Blister packs: Peel open the blister by pulling back the foil backing. Do not push the capsule through the foil, as this can damage the capsule.
- Bottle packaging: Once a bottle is opened, the capsules must be used within 4 months. Write the date of opening on the bottle label. Close the bottle tightly after each use.
- Children: Keep out of the reach and sight of children. The child-proof closure on the bottle must be used correctly.
- Expired medication: Do not use dabigatran after the expiry date printed on the packaging. Return any unused or expired capsules to your pharmacist for safe disposal. Do not throw them in household waste or flush them down the toilet.
If you notice that the capsules have changed in appearance (discoloration, swelling, softening, or a strong unusual odor), do not take them and contact your pharmacist. These changes may indicate moisture damage and the capsules may no longer be effective or safe.
What Does Dabigatran Etexilate Sandoz Contain?
Understanding the composition of your medication can be important, particularly if you have known allergies to specific ingredients or if you follow a restricted diet. The following information describes the composition of Dabigatran etexilate Sandoz hard capsules.
Active Ingredient
The active substance is dabigatran etexilate (as dabigatran etexilate mesilate). The 75 mg capsule contains 75 mg of dabigatran etexilate (equivalent to 86.48 mg of dabigatran etexilate mesilate). The mesilate salt form is used to optimize the pharmaceutical properties of the active ingredient. After oral administration, dabigatran etexilate is rapidly converted by esterases to the active compound dabigatran, which is responsible for the anticoagulant effect.
Excipients (Inactive Ingredients)
The excipients in the capsule formulation play important roles in drug delivery and stability:
- Tartaric acid: Creates an acidic microenvironment around the drug pellets to enhance dissolution and absorption of dabigatran etexilate. This is essential because dabigatran etexilate has pH-dependent solubility, with markedly better solubility at low pH. The tartaric acid core is also thought to be responsible for the dyspepsia reported by some patients.
- Acacia (gum arabic): Used as a binding agent in the pellet core to help maintain the structural integrity of the drug pellets.
- Hypromellose (hydroxypropyl methylcellulose): Used as a coating material for the pellets to control drug release.
- Dimethicone: An anti-foaming agent that aids in the manufacturing process.
- Talc: Used as a glidant to improve the flow properties of the pellets during capsule filling.
- Hydroxypropylcellulose: Used as a binding agent in the pellet formulation.
The capsule shell is made of hypromellose and may contain titanium dioxide (E171), carrageenan, potassium chloride, and printing ink. The specific colors and markings of the capsule shells differ between the 75 mg, 110 mg, and 150 mg strengths to help distinguish them and reduce the risk of dosing errors.
Dabigatran etexilate Sandoz capsules do not contain lactose, gluten, sucrose, or any animal-derived gelatin (the capsule shell is made from hypromellose, a plant-derived polymer). They contain no significant amount of sodium. However, if you have a known allergy to any of the listed excipients, inform your doctor or pharmacist before starting treatment.
Frequently Asked Questions About Dabigatran Etexilate Sandoz
References
This article is based on internationally recognized, peer-reviewed medical sources. All information has been reviewed for accuracy according to current evidence-based guidelines.
- Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151. doi:10.1056/NEJMoa0905561 – RE-LY trial. Evidence level: 1A.
- Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342–2352. doi:10.1056/NEJMoa0906598 – RE-COVER trial. Evidence level: 1A.
- European Medicines Agency (EMA). Pradaxa (dabigatran etexilate) – Summary of Product Characteristics. Updated 2025. EMA EPAR: Pradaxa
- U.S. Food and Drug Administration (FDA). PRADAXA (dabigatran etexilate mesylate) – Prescribing Information. Updated 2024. FDA Label
- Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. Eur Heart J. 2021;42(5):373–498. doi:10.1093/eurheartj/ehaa612 – ESC AF Guidelines. Evidence level: 1A.
- Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal – full cohort analysis. N Engl J Med. 2017;377(5):431–441. doi:10.1056/NEJMoa1707278 – RE-VERSE AD trial. Evidence level: 1B.
- World Health Organization (WHO). WHO Model List of Essential Medicines, 23rd list. 2023. WHO Essential Medicines
This article follows the GRADE (Grading of Recommendations Assessment, Development and Evaluation) framework. Level 1A represents the highest quality of evidence, based on systematic reviews and meta-analyses of well-conducted randomized controlled trials with consistent results. The RE-LY, RE-COVER, and RE-VERSE AD trials represent landmark evidence that forms the foundation of international guidelines for dabigatran use.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in cardiology, hematology, and clinical pharmacology.
Medical Content
iMedic Cardiology Editorial Team – specialist physicians in cardiology and internal medicine with clinical experience in anticoagulation management
Medical Review
iMedic Medical Review Board – independent panel verifying accuracy against EMA SmPC, FDA label, ESC, and ISTH guidelines
Pharmacology Review
iMedic Clinical Pharmacology Team – specialists in drug interactions, pharmacokinetics, and medication safety
Accessibility & SEO
iMedic Digital Health Team – ensuring WCAG 2.2 AAA compliance and optimal search visibility
All content follows the GRADE evidence framework and is reviewed according to international medical guidelines. iMedic receives no commercial funding from pharmaceutical companies.